budesonide indications/contra

Stem definitionDrug idCAS RN
steroids for topical use, acetal derivatives 419 51333-22-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • budesonide
  • barazone
  • budesomide
  • budeson
A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.
  • Molecular weight: 430.54
  • Formula: C25H34O6
  • CLOGP: 2.90
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 93.06
  • ALOGS: -3.97
  • ROTB: 4

Drug dosage:

DoseUnitRoute
9 mg O
0.20 mg N
0.80 mg Inhal.aerosol
0.80 mg Inhal.powder
1.50 mg Inhal.solution

Approvals:

DateAgencyCompanyOrphan
Feb. 14, 1994 FDA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Asthma 1569.08 23.99 401 5241 12001 3368216
Dyspnoea 1448.39 23.99 630 5012 102304 3277913
Chronic obstructive pulmonary disease 621.78 23.99 190 5452 10819 3369398
Drug ineffective 567.20 23.99 352 5290 115738 3264479
Cough 543.15 23.99 241 5401 39617 3340600
Off label use 514.88 23.99 255 5387 53722 3326495
Intentional product misuse 485.53 23.99 163 5479 12538 3367679
Wheezing 401.80 23.99 127 5515 8044 3372173
Cushing's syndrome 388.99 23.99 83 5559 1063 3379154
Circumstance or information capable of leading to medication error 367.92 23.99 89 5553 2053 3378164
Drug dose omission 325.67 23.99 168 5474 38264 3341953
Dysphonia 313.07 23.99 103 5539 7401 3372816
Chest discomfort 308.86 23.99 127 5515 17158 3363059
Condition aggravated 260.67 23.99 146 5496 39087 3341130
Pneumonia 225.40 23.99 165 5477 69978 3310239
Palpitations 219.76 23.99 103 5539 18980 3361237
Product quality issue 203.62 23.99 109 5533 26626 3353591
Device malfunction 184.65 23.99 61 5581 4423 3375794
Throat irritation 170.88 23.99 60 5582 5234 3374983
Tremor 168.53 23.99 98 5544 28046 3352171
Chest pain 159.86 23.99 108 5534 40167 3340050
Adrenal insufficiency 146.71 23.99 42 5600 1879 3378338
Feeling jittery 146.58 23.99 44 5598 2327 3377890
Malaise 137.58 23.99 120 5522 65057 3315160
Intentional device misuse 135.80 23.99 29 5613 371 3379846
Bronchospasm 132.20 23.99 47 5595 4247 3375970
Drug interaction 131.90 23.99 102 5540 46710 3333507
Oropharyngeal pain 131.38 23.99 63 5579 12171 3368046
Product use issue 129.47 23.99 68 5574 15933 3364284
Candida infection 126.04 23.99 44 5598 3768 3376449

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC A07EA06 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFLAMMATORY AGENTS
Corticosteroids acting locally
ATC D07AC09 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, potent (group III)
ATC R01AD05 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Corticosteroids
ATC R03BA02 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Glucocorticoids
ATC R03AK07 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AK12 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
FDA EPC N0000175576 Corticosteroid
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
MeSH PA D000305 Adrenal Cortex Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D001337 Autonomic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D006730 Hormones, Hormone Substitutes, and Hormone Antagonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:35472 anti-inflammatory drug

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Crohn's disease indication 34000006
Allergic rhinitis indication 61582004
Asthma indication 195967001 DOID:2841
Asthma management indication 406162001
Crohn's disease in remission indication 426549001
Allergic Rhinitis Prevention indication
Chronic Non-Allergic Rhinitis indication
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Ocular hypertension contraindication 4210003 DOID:9282
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Epistaxis contraindication 12441001
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Disease caused by parasite contraindication 17322007
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Glaucoma contraindication 23986001 DOID:1686
Acute tuberculosis contraindication 25629007
Viral disease contraindication 34014006 DOID:934
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Hypercortisolism contraindication 47270006 DOID:3947
Chronic heart failure contraindication 48447003
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Congenital hyperammonemia, type I contraindication 62522004 DOID:9280
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Perforation of nasal septum contraindication 80142000
Hyperglycemia contraindication 80394007 DOID:4195
Open-angle glaucoma contraindication 84494001 DOID:1067
Bacterial infectious disease contraindication 87628006 DOID:104
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Operation on nose contraindication 88733004
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002 DOID:1826
Disorder of muscle contraindication 129565002 DOID:423
Pulmonary tuberculosis contraindication 154283005 DOID:2957
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Varicella-zoster virus infection contraindication 309465005
Osteopenia contraindication 312894000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Oropharyngeal Candidiasis contraindication
Ornithine Carbamyltransferase Deficiency contraindication
Nasal Septal Ulcers contraindication
Uncontrolled Bacterial Infections contraindication
Nasal Trauma contraindication
Untreated Fungal Infection contraindication
Arginosuccinate Lyase Deficiency contraindication
Nasal Candidiasis contraindication
Severe chronic obstructive pulmonary disease off-label use 313299006

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.8 acidic
pKa2 12.78 acidic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.08MG/INH PULMICORT FLEXHALER ASTRAZENECA N021949 July 12, 2006 RX POWDER, METERED INHALATION 6027714 Jan. 9, 2018 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
0.16MG/INH PULMICORT FLEXHALER ASTRAZENECA N021949 July 12, 2006 RX POWDER, METERED INHALATION 6027714 Jan. 9, 2018 MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7897646 Sept. 9, 2018 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7897646 Sept. 9, 2018 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8461211 Sept. 9, 2018 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8461211 Sept. 9, 2018 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.25MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 7524834 Nov. 11, 2018 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
0.5MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 7524834 Nov. 11, 2018 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
1MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 7524834 Nov. 11, 2018 TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
0.25MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6598603 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
0.25MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6899099 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
0.5MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6598603 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
0.5MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6899099 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
1MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6598603 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
1MG/2ML PULMICORT RESPULES ASTRAZENECA PHARMS N020929 Aug. 8, 2000 RX SUSPENSION INHALATION 6899099 Dec. 23, 2018 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE
9MG UCERIS VALEANT PHARMS INTL N203634 Jan. 14, 2013 RX TABLET, EXTENDED RELEASE ORAL 7410651 June 9, 2020 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
9MG UCERIS VALEANT PHARMS INTL N203634 Jan. 14, 2013 RX TABLET, EXTENDED RELEASE ORAL 9320716 June 9, 2020 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
9MG UCERIS VALEANT PHARMS INTL N203634 Jan. 14, 2013 RX TABLET, EXTENDED RELEASE ORAL 9532954 June 9, 2020 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
9MG UCERIS VALEANT PHARMS INTL N203634 Jan. 14, 2013 RX TABLET, EXTENDED RELEASE ORAL RE43799 June 9, 2020 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 7759328 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8143239 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION 8575137 Jan. 29, 2023 USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
9MG UCERIS VALEANT PHARMS INTL N203634 Jan. 14, 2013 RX TABLET, EXTENDED RELEASE ORAL 9192581 Sept. 7, 2031 INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
3MG ENTOCORT EC PERRIGO PHARMA INTL N021324 Oct. 2, 2001 RX CAPSULE ORAL April 29, 2019 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
3MG ENTOCORT EC PERRIGO PHARMA INTL N021324 Oct. 2, 2001 RX CAPSULE ORAL April 29, 2019 NEW PATIENT POPULATION
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION Jan. 27, 2020 NEW PATIENT POPULATION
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION July 27, 2020 PEDIATRIC EXCLUSIVITY
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION Sept. 11, 2020 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION Sept. 11, 2020 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.08MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION Dec. 20, 2020 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
0.16MG/INH SYMBICORT ASTRAZENECA N021929 July 21, 2006 RX AEROSOL, METERED INHALATION Dec. 20, 2020 INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST EC50 10.30 WOMBAT-PK CHEMBL
Interleukin-5 Cytokine IC50 9.92 WOMBAT-PK
Matrix metalloproteinase-9 Enzyme IC50 5.70 DRUG MATRIX
Multidrug resistance protein 1 Transporter WOMBAT-PK
Mineralocorticoid receptor Nuclear hormone receptor AGONIST EC50 7.85 IUPHAR
Interferon gamma Cytokine IC50 9.50 WOMBAT-PK
Progesterone receptor Nuclear hormone receptor AGONIST EC50 7.55 IUPHAR
Androgen receptor Transcription factor Ki 5.96 DRUG MATRIX
Progesterone receptor Transcription factor Ki 7.57 DRUG MATRIX
Interleukin-5 Unclassified IC50 4.58 CHEMBL
Glucocorticoid receptor Transcription factor IC50 8.54 CHEMBL

External reference:

scroll-->
IDSource
4020889 VUID
N0000148384 NUI
C0054201 UMLSCUI
7434 IUPHAR_LIGAND_ID
D00246 KEGG_DRUG
4020889 VANDF
N0000148384 NDFRT
N0000005806 NDFRT
004214 NDDF
44092 MMSL
19831 RXNORM
108622005 SNOMEDCT_US
395726003 SNOMEDCT_US
4303 MMSL
d04276 MMSL
CHEMBL1370 ChEMBL_ID
5281004 PUBCHEM_CID
DB01222 DRUGBANK_ID
Q3OKS62Q6X UNII
4145 INN_ID
D019819 MESH_DESCRIPTOR_UI
CHEBI:3207 CHEBI
8W5 PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0093-6815 SUSPENSION 0.25 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0093-6816 SUSPENSION 0.50 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0093-6817 SUSPENSION 1 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0093-7445 CAPSULE, DELAYED RELEASE PELLETS 3 mg ORAL ANDA 18 sections
Budesonide Inhalation HUMAN PRESCRIPTION DRUG LABEL 1 0115-1687 SUSPENSION 0.25 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide Inhalation HUMAN PRESCRIPTION DRUG LABEL 1 0115-1689 SUSPENSION 0.50 mg RESPIRATORY (INHALATION) ANDA 17 sections
SYMBICORT HUMAN PRESCRIPTION DRUG LABEL 1 0186-0370 AEROSOL 160 ug RESPIRATORY (INHALATION) NDA 18 sections
SYMBICORT HUMAN PRESCRIPTION DRUG LABEL 1 0186-0372 AEROSOL 80 ug RESPIRATORY (INHALATION) NDA 18 sections
ENTOCORT HUMAN PRESCRIPTION DRUG LABEL 1 0186-0702 CAPSULE 3 mg ORAL NDA 17 sections
PULMICORT HUMAN PRESCRIPTION DRUG LABEL 1 0186-0916 AEROSOL, POWDER 180 ug RESPIRATORY (INHALATION) NDA 17 sections
PULMICORT HUMAN PRESCRIPTION DRUG LABEL 1 0186-0917 AEROSOL, POWDER 90 ug RESPIRATORY (INHALATION) NDA 17 sections
PULMICORT RESPULES HUMAN PRESCRIPTION DRUG LABEL 1 0186-1988 SUSPENSION 0.25 mg RESPIRATORY (INHALATION) NDA 17 sections
PULMICORT RESPULES HUMAN PRESCRIPTION DRUG LABEL 1 0186-1989 SUSPENSION 0.50 mg RESPIRATORY (INHALATION) NDA 17 sections
PULMICORT RESPULES HUMAN PRESCRIPTION DRUG LABEL 1 0186-1990 SUSPENSION 1 mg RESPIRATORY (INHALATION) NDA 17 sections
Budesonide HUMAN OTC DRUG LABEL 1 0363-0048 SPRAY, METERED 32 ug NASAL ANDA 9 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0378-7155 CAPSULE 3 mg ORAL ANDA 18 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0487-9601 INHALANT 0.25 mg RESPIRATORY (INHALATION) ANDA 18 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0487-9701 INHALANT 0.50 mg RESPIRATORY (INHALATION) ANDA 18 sections
Budesonide HUMAN OTC DRUG LABEL 1 0536-1112 SPRAY, METERED 32 ug NASAL ANDA 9 sections
Entocort EC HUMAN PRESCRIPTION DRUG LABEL 1 0574-9850 CAPSULE 3 mg ORAL NDA 19 sections
Budesonide Inhalation HUMAN PRESCRIPTION DRUG LABEL 1 0591-3767 SUSPENSION 0.25 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide Inhalation HUMAN PRESCRIPTION DRUG LABEL 1 0591-3768 SUSPENSION 0.50 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0781-7515 SUSPENSION 0.25 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0781-7516 SUSPENSION 0.50 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN PRESCRIPTION DRUG LABEL 1 0781-7517 SUSPENSION 1 mg RESPIRATORY (INHALATION) ANDA 17 sections
Budesonide HUMAN OTC DRUG LABEL 1 11822-6000 SPRAY, METERED 32 ug NASAL ANDA 9 sections
Budesonide HUMAN OTC DRUG LABEL 1 21130-710 SPRAY, METERED 32 ug NASAL ANDA 9 sections
PULMICORT HUMAN PRESCRIPTION DRUG LABEL 1 21695-291 AEROSOL, POWDER 90 ug RESPIRATORY (INHALATION) NDA 17 sections
Budesonide HUMAN OTC DRUG LABEL 1 36800-113 SPRAY, METERED 32 ug NASAL ANDA 9 sections
Budesonide HUMAN OTC DRUG LABEL 1 46122-389 SPRAY, METERED 32 ug NASAL ANDA 9 sections